Document is current
Any future updates will be listed below
-
Authors
Nakajima, Kenichi https://orcid.org/0000-0001-7188-8746
Matsumura, Takeshi
Komatsu, Junji
Wakabayashi, Hiroshi
Ono, Kenjiro
Kinuya, Seigo
-
Funding
Funding for this research was provided by:
Japan Society for the Promotion of Science (23K07203)
Kanazawa University
- License Information
-
More Information
Article History
Received: 19 February 2024
Accepted: 31 May 2024
First Online: 13 June 2024
Declarations
:
: K. Nakajima has a collaborative research agreement with PDRadiopharma, Tokyo, Japan, that markets <sup>123</sup>I-MIBG in Japan. He also belongs to endowed department funded by PDRadiopharma, Tokyo, Japan, Nihon Medi-Physics, Tokyo, Japan, and Siemens Healthcare, Tokyo, Japan.
: The datasets generated during and/or analyzed during the current study are available from the corresponding author on reasonable request.
: The Ethics Committee at Kanazawa University approved this study (2020–036 [3379]). The need for patient consent was waived due to retrospective nature of the study, and the opportunity to opt out was provided on the Kanazawa University website.
